Skip to main content
Premium Trial:

Request an Annual Quote

Lunaphore Technologies Raises Additional $2.1M in Series C Financing

NEW YORK Lunaphore Technologies on Tuesday announced it has raised CHF 2 million ($2.1 million) in Series C2 financing, bringing the total revenues for its Series C round to CHF 25 million.

Swiss Entrepreneurs Fund invested all CHF 2 million in the Series C2 financing round, bringing its total investment in Lunaphore to CHF 5 million. The Swiss Entrepreneurs fund is linked to the Swiss Entrepreneurs Foundation, whose focus is to invest in Swiss startups and small- and medium-sized enterprises in a growth phase, Lunaphore said.

In February, the Lausanne, Switzerland-based company had announced it raised CHF 23 million in its Series C round.

The proceeds from the overall Series C financing will be dedicated to market and product expansion, including a US market entry, the ramp up of activities in Europe, and the development of next-generation instruments, the firm said.

Lunaphore is developing next-generation tissue autostainers that use microfluidics to perform assays on cancer patient tissue samples.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.